Guardant Health Appoints Terilyn Juarez Monroe as Chief People Officer
02 Janvier 2024 - 5:00PM
Business Wire
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology
company, today announced the addition of Terilyn Juarez Monroe as
the company’s chief people officer, effective immediately.
In the newly-created role, Monroe will lead the human resources
function, including people operations; cultural and organizational
transformation; talent acquisition; and diversity and inclusion
initiatives. Amelia Merrill, who previously served as senior vice
president of people, is transitioning to an advisory role with the
company.
“Terilyn brings deep expertise in leading, transforming, and
scaling the human resources function at rapidly growing companies,
and we welcome her leadership as we pursue our exciting next
chapter,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO.
“She will play a pivotal role in advancing our mission-driven
culture centered on patients, attracting world-class talent, and
making Guardant an even greater place to work.”
Prior to joining Guardant, Monroe held numerous human resources
leadership roles, including as chief people officer at Bonterra,
Varian, and Acxiom. She also was chief diversity officer at Intuit,
where she led the company’s diversity and inclusion efforts.
“I am excited to join Guardant to lead the scaling, development
and experience of our world-class team and culture in support of
our mission to advance cancer care for patients globally,” said
Terilyn Juarez Monroe. “Throughout my career, I have been drawn to
companies with an aspiration to leave a bigger impact on the world.
Guardant has the potential to revolutionize cancer screening and
detection, giving patients more quality time with their families. I
look forward to all that we will achieve.”
Monroe serves on the board of directors for CASSY, a nonprofit
organization focused on counseling and support services for youth.
Monroe holds a bachelor’s degree from San Jose State
University.
About Guardant Health
Guardant Health is a leading precision oncology company focused
on guarding wellness and giving every person more time free from
cancer. Founded in 2012, Guardant is transforming patient care by
providing critical insights into what drives disease through its
advanced blood and tissue tests, real-world data and AI analytics.
Guardant tests help improve outcomes across all stages of care,
including screening to find cancer early, monitoring for recurrence
in early-stage cancer, and helping doctors select the best
treatment for patients with advanced cancer. For more information,
visit guardanthealth.com and follow the company on LinkedIn, X
(Twitter) and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240102537486/en/
Investor Contact: investors@guardanthealth.com
Media Contact: Melissa Marasco press@guardanthealth.com
+1 650-647-3711
Guardant Health (NASDAQ:GH)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Guardant Health (NASDAQ:GH)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024